Senate launches investigation into high prices of Ozempic and Wegovy in the U.S.
Publishing timestamp: 2024-04-24 16:18:33
Summary
The U.S. Senate is investigating the high prices of Novo Nordisk's weight loss and diabetes drugs Ozempic and Wegovy. Senator Bernie Sanders has asked the CEO about the pricing and research and development costs. Novo Nordisk charges significantly more in the U.S. compared to other countries, and Sanders is calling for a reduction in prices to make the drugs more accessible. Novo Nordisk has until May 8 to respond to questions about drug pricing.
Sentiment: MIXED
Keywords: biotech and pharmaceuticals, social issues, politics, breaking news: politics, business news, novo nordisk a/s, united states, health care industry,